Journey Medical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Journey Medical şirketinin toplam hissedar öz sermayesi $10.9M ve toplam borcu $21.0M olup, bu da borç-öz sermaye oranını 192.5% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $64.0M ve $53.1M dir.

Anahtar bilgiler

192.5%

Borç/özkaynak oranı

US$21.04m

Borç

Faiz karşılama oranı	n/a
Nakit	US$22.46m
Eşitlik	US$10.93m
Toplam yükümlülükler	US$53.12m
Toplam varlıklar	US$64.04m

Son finansal sağlık güncellemeleri

Here's Why Journey Medical (NASDAQ:DERM) Has A Meaningful Debt Burden

Sep 14

Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?

May 06

Recent updates

Journey Medical Corporation (NASDAQ:DERM) Shares Fly 31% But Investors Aren't Buying For Growth

Oct 03

Here's Why Journey Medical (NASDAQ:DERM) Has A Meaningful Debt Burden

Sep 14

Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?

May 06

Journey Medical Corporation (NASDAQ:DERM) Not Doing Enough For Some Investors As Its Shares Slump 31%

Mar 11

Journey Medical Corporation's (NASDAQ:DERM) 33% Dip In Price Shows Sentiment Is Matching Revenues

Jan 18

Journey Medical Corporation's (NASDAQ:DERM) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Nov 10

US$12.00: That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After Its Latest Results

May 12

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: DERM 'nin kısa vadeli varlıkları ( $46.2M ) kısa vadeli yükümlülüklerini ( $33.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: DERM şirketinin kısa vadeli varlıkları ( $46.2M ) uzun vadeli yükümlülüklerini ( $19.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: DERM şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: DERM şirketinin borç/öz sermaye oranının son 5 yılda azalıp azalmadığını belirlemek için yeterli veri yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: DERM şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: DERM un, serbest nakit akışı her yıl % 19.9 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Journey Medical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why Journey Medical (NASDAQ:DERM) Has A Meaningful Debt Burden

Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?

Journey Medical Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum Stockholders’ Equity Requirement for Continued Listing on The Nasdaq Capital Market

Journey Medical Corporation announced delayed 10-Q filing

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 17%

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Journey Medical Corporation (NASDAQ:DERM) Shares Fly 31% But Investors Aren't Buying For Growth

Here's Why Journey Medical (NASDAQ:DERM) Has A Meaningful Debt Burden

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Journey Medical Corporation to Report Q2, 2024 Results on Aug 12, 2024

New minor risk - Market cap size

CFO & Corporate Controller recently sold US$51k worth of stock

Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Journey Medical Corporation to Report Q1, 2024 Results on May 13, 2024

Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?

Journey Medical Corporation Appoints Joseph M. Benesch as Chief Financial Officer

Journey Medical Corporation, Annual General Meeting, Jun 25, 2024

New major risk - Share price stability

Consensus EPS estimates fall by 196%

Independent Director recently bought US$104k worth of stock

Full year 2023 earnings: EPS misses analyst expectations

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

Journey Medical Corporation to Report Fiscal Year 2023 Results on Mar 21, 2024

Journey Medical Corporation (NASDAQ:DERM) Not Doing Enough For Some Investors As Its Shares Slump 31%

Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 on Microbial Flora of Healthy Adults At 2024 Annual Meeting

Journey Medical Corporation's (NASDAQ:DERM) 33% Dip In Price Shows Sentiment Is Matching Revenues

Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

New minor risk - Profitability

Journey Medical Corporation Announces Resignation of Jeffrey Paley as Member of the Board of Directors

Journey Medical Corporation Announces Successful Completion of Pre-Nda Meeting with the Fda for Dfd-29 to Treat Rosacea

Consensus revenue estimates increase by 26%

Journey Medical Corporation's (NASDAQ:DERM) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Journey Medical Corporation to Report Q3, 2023 Results on Nov 07, 2023

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29

Independent Director recently bought US$98k worth of stock

Independent Director recently bought US$89k worth of stock

Executive Chairman recently bought US$223k worth of stock

Journey Medical Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum Stockholders’ Equity Requirement for Continued Listing on The Nasdaq Capital Market

Price target increased by 30% to US$6.50

Journey Medical Corporation Announces Impairment Charges for the Second Quarter Ended June 30, 2023

Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 Mg) on Microbial Flora of Healthy Adult Subjects

Journey Medical Corporation announced delayed 10-Q filing

Journey Medical Corporation to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: EPS misses analyst expectations

Journey Medical Corporation Announces CFO Changes, Effective January 27, 2023

Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 Mg) for the Treatment of Papulopustular Rosacea

Consensus EPS estimates fall by 23%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$7.33

Journey Medical Corporation to Report Q3, 2022 Results on Nov 10, 2022

Consensus EPS estimates fall by 14%

Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating Dfd-29 (Minocycline Modified Release Capsules 40 Mg) for the Treatment of Papulopustular Rosacea

Consensus EPS estimates fall by 36%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Journey Medical Corporation to Report Q2, 2022 Results on Aug 09, 2022

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 14%

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

US$12.00: That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After Its Latest Results

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin